Arvelle Therapeutics GmbH (aquired by Angelini Pharma)

Arvelle Therapeutics is a biopharmaceutical company with the mission of bringing innovative solutions to patients suffering from CNS disorders. Arvelle is responsible for the development and commercialization of cenobamate, an investigational antiepileptic drug, in the European market. Arvelle received one of the largest initial financing commitments for a European-focused biopharmaceutical company.